BioCopy Advances AI Driven Cancer Therapies with Strategic Investment from Haute Capital
As part of a Series A financing round scheduled to close on March 31, 2026, Haute Capital Partners has made a strategic investment in BioCopy
Dr. Matthias Wiedenfels discusses BioCopy’s breakthrough AI-powered approach on BioBiz Buzz Podcast
“Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech”
Ranked among Germany’s biotech pioneers of the coming decade
WirtschaftsWoche has selected Matthias Wiedenfels as a winner of “Germany’s 30 by 2030”
BioCopy chooses Genedata for AI-powered Multi-specific Antibody Discovery
Next step towards BioCopys AI-powered high-quality engineering of next-generation cancer therapeutics
BioCopy expands corporate portfolio with acquisition of Perspix Biotech GmbH
Recent company developments across operations, financing, and organizational build out.